ARCHIVES

Drug Development: ODAC Discussion May Offer Clues For Sponsors of Cytostatic Drugs

This article is from The Cancer Letter archive.

Vol. 25 No. 24 | June 16, 1999

Download PDF Visit The Full Archive

Related Articles

Elevated Baseline Glucose Levels Associated With Higher Cancer Risk

November 25, 2011

Professional Groups Agree On Colon Cancer Screening Guidelines.

March 7, 2008

Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication

November 25, 2011

NCI Reorganization: DEC Epidemiology Stays In Place, DCPC To Build Its Own – No Decision Yet Enters, Other DCPC Program – CIS Moved To OCC, ICIC ut Of OIA

June 24, 1988

ODAC Rejects Temodal for Melanoma After Discussion Of Approval Standards

April 2, 1999

The Cancer Letter’s Paul Goldberg Wins Journalism Award

April 10, 2009